Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2009

Idera to Obtain $3.8M from Merck KGaA for Progress of Anticancer Agent

  • Idera Pharmaceuticals expects to receive €3.0 million, or about $3.8 million, as a milestone fee from Merck KGaA. The payment is due to the dosing of the first patient with colorectal cancer in a study of IMO-2055 in combination with Erbitux® and Camptosar® in patients.

    This marks the first reported milestone achievement under the $421 million deal inked between the firms in December 2007. Idera anticipates receiving the payment during the second quarter.

    Idera received $40 million at signing of the worldwide licensing and collaboration deal. It covers two toll-like receptor 9 (TLR9) agonists from Idera’s pipeline for the treatment of cancer. Under this partnership, IMO-2055 is also being studied in a Phase Ib trial in combination with Tarceva® and Avastin® in patients with advanced non-small-cell lung cancer.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »